Difference between revisions of "Mechlorethamine (Mustargen)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(14 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Nitrogen mustard, alkylator.  Crosslinks DNA, interfering with cell replication.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Mechlorethamine.pdf Mechlorethamine (Mustargen) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/mechlorethamine.pdf Mechlorethamine (Mustargen) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Nitrogen mustard, alkylator.  Crosslinks DNA, interfering with cell replication.<ref name="insert">[http://patient.cancerconsultants.com/druginserts/Mechlorethamine.pdf Mechlorethamine (Mustargen) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/mechlorethamine.pdf Mechlorethamine (Mustargen) package insert (locally hosted backup)]</ref>
−
<br>Route: IV, intracavitary
+
<br>Route: IV, intracavitary, topical
 
<br>Extravasation: [[vesicant]]
 
<br>Extravasation: [[vesicant]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>  
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
−
*[[Hodgkin lymphoma]]
+
*[[HIV-associated lymphoma]]
 +
*[[Classical Hodgkin lymphoma]]
  
−
==Historical reference==
+
==Diseases for which it was used==
−
# Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946 Sep 21;132:126-32. [http://jamanetwork.com/journals/jama/fullarticle/288442 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20997191 PubMed]
+
*[[Diffuse large B-cell lymphoma - historical|Diffuse large B-cell lymphoma]]
−
# Meyer AH, Overmiller WC. The use of nitrogen mustard in Hodgkin's disease and lymphosarcoma. Ann Intern Med. 1949 Feb;30(2):381-6. [http://annals.org/aim/article/673986/use-nitrogen-mustard-hodgkin-s-disease-lymphosarcoma link to original article][https://www.ncbi.nlm.nih.gov/pubmed/18109292 PubMed]
+
*[[Follicular lymphoma - historical|Follicular lymphoma]]
  
 
==Patient drug information==
 
==Patient drug information==
Line 18: Line 19:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 3/15/1949: Initial FDA approval ('''This is the first chemotherapy agent ever approved''')
+
* 1949-03-15: Initial FDA approval ('''This is the first chemotherapy agent ever approved''')
−
* 2/9/2004 (only label available at Drugs @ FDA):
+
* 2004-02-09 (only label available at Drugs @ FDA):
 
# "Administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma."
 
# "Administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma."
−
# "Administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion."  
+
# "Administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion."
−
+
 
 
==Also known as==
 
==Also known as==
−
*'''Generic name:''' nitrogen mustard
+
*'''Generic name:''' chlormethine, nitrogen mustard
−
*'''Brand names:''' Chlormethine, Mustargen, Mustine
+
*'''Brand names:''' Ledaga, Mustargen, Mustine
  
 
==References==
 
==References==
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
 
[[Category:Intracavitary medications]]
 
[[Category:Intracavitary medications]]
−
[[Category:Vesicant chemotherapy]]
+
[[Category:Topical medications]]
 +
[[Category:Vesicant]]
 
[[Category:Alkylating agents]]
 
[[Category:Alkylating agents]]
 
[[Category:Nitrogen mustards]]
 
[[Category:Nitrogen mustards]]
  
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:HIV-associated lymphoma medications]]
 +
[[Category:Classical Hodgkin lymphoma medications]]
 +
 
 +
[[Category:Diffuse large B-cell lymphoma medications (historic)]]
 +
[[Category:Follicular lymphoma medications (historic)]]
  
−
[[Category:Drugs FDA approved in 1949]]
+
[[Category:FDA approved in 1949]]

Latest revision as of 01:06, 29 June 2024

General information

Class/mechanism: Nitrogen mustard, alkylator. Crosslinks DNA, interfering with cell replication.[1][2]
Route: IV, intracavitary, topical
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 1949-03-15: Initial FDA approval (This is the first chemotherapy agent ever approved)
  • 2004-02-09 (only label available at Drugs @ FDA):
  1. "Administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma."
  2. "Administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion."

Also known as

  • Generic name: chlormethine, nitrogen mustard
  • Brand names: Ledaga, Mustargen, Mustine

References

  1. ↑ 1.0 1.1 Mechlorethamine (Mustargen) package insert
  2. ↑ Mechlorethamine (Mustargen) package insert (locally hosted backup)
  3. ↑ Mechlorethamine (Mustargen) patient drug information (Chemocare)
  4. ↑ Mechlorethamine (Mustargen) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Mechlorethamine_(Mustargen)&oldid=87398"